- Home
- FCAP vs CNTX Comparison
FCAP vs CNTX Comparison
Compare FCAP & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCAP
- CNTX
- Stock Information
- Founded
- FCAP 1891
- CNTX 2015
- Country
- FCAP United States
- CNTX United States
- Employees
- FCAP N/A
- CNTX N/A
- Industry
- FCAP Savings Institutions
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- FCAP Finance
- CNTX Health Care
- Exchange
- FCAP Nasdaq
- CNTX Nasdaq
- Market Cap
- FCAP 125.9M
- CNTX 113.0M
- IPO Year
- FCAP 1999
- CNTX 2021
- Fundamental
- Price
- FCAP $44.01
- CNTX $1.11
- Analyst Decision
- FCAP
- CNTX Strong Buy
- Analyst Count
- FCAP 0
- CNTX 7
- Target Price
- FCAP N/A
- CNTX $5.40
- AVG Volume (30 Days)
- FCAP 3.6K
- CNTX 437.7K
- Earning Date
- FCAP 10-24-2025
- CNTX 11-05-2025
- Dividend Yield
- FCAP 2.80%
- CNTX N/A
- EPS Growth
- FCAP 25.19
- CNTX N/A
- EPS
- FCAP 4.41
- CNTX N/A
- Revenue
- FCAP $47,323,000.00
- CNTX N/A
- Revenue This Year
- FCAP N/A
- CNTX N/A
- Revenue Next Year
- FCAP N/A
- CNTX N/A
- P/E Ratio
- FCAP $10.07
- CNTX N/A
- Revenue Growth
- FCAP 15.22
- CNTX N/A
- 52 Week Low
- FCAP $28.50
- CNTX $0.49
- 52 Week High
- FCAP $53.85
- CNTX $2.25
- Technical
- Relative Strength Index (RSI)
- FCAP 57.27
- CNTX 46.80
- Support Level
- FCAP $42.71
- CNTX $1.04
- Resistance Level
- FCAP $44.00
- CNTX $1.15
- Average True Range (ATR)
- FCAP 0.80
- CNTX 0.09
- MACD
- FCAP 0.20
- CNTX -0.03
- Stochastic Oscillator
- FCAP 100.00
- CNTX 19.70
About FCAP First Capital Inc.
First Capital Inc is the financial holding company of First Harrison Bank. Through its subsidiary, it operates as a federally-chartered savings bank that provides banking services to individuals and business customers across locations in America. The bank offers various loans which include residential loans, construction loans, commercial real estate loans and commercial business loans. It also provides consumer loans such as home equity and second mortgage loans, and automobile and truck loans.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.